+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors

Current Diabetes Reviews 4(2): 101-109

Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive beta cell dysfunction as well as abnormalities in pancreatic alpha cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in beta cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon like peptide 1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 052946069

Download citation: RISBibTeXText

PMID: 18473757

Related references

Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and Dpp-4 Inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technology and Therapeutics 8(3): 385-396, 2006

Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. Best Practice and Research. Clinical Endocrinology and Metabolism 23(4): 513-523, 2009

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arquivos Brasileiros de Endocrinologia e Metabologia 52(6): 1039-1049, 2008

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. PharmacoTherapy 26(3): 360-374, 2006

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes. Revue Medicale Suisse 3(122): 1884 1886-8, 2007

Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. American Journal of Medicine 123(7): S2, 2010

Incretin mimetics as emerging treatments for type 2 diabetes. Annals of PharmacoTherapy 39(1): 110-118, 2005

Incretin-based therapies: mimetics versus protease inhibitors. Trends in Endocrinology and Metabolism: Tem 18(6): 240-245, 2007

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2012

Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Journal of the American Academy of Nurse Practitioners 20(Suppl. 1): 7, 2008

Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes. Primary Care Diabetes 1(2): 103-105, 2007

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discovery Today 10(10): 703-710, 2005